Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Neurology | Family Medicine
Disease Category: Alzheimer's Disease
Location: United States, FL

Clinical Trial Details

Overview

Research Study Summary

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

Purpose

The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks.

To Learn more

CW ID: 203170
Date Last Changed: November 6, 2014

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
50 to 85 Years
Overall Status
Recruiting
Lead Sponsor
Merck Sharp & Dohme Corp
Facility Type
N/A

Contact

Jill Smith
University of South Florida - USF Health Byrd Alzheimer's Institute
4001 Fletcher Avenue
Tampa, FL 33613
Phone: (813)974-1294

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.